Your session is about to expire
← Back to Search
Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel for Gastric Cancer
Study Summary
This trial is testing a new drug, cinrebafusp alfa, to see if it can help treat stomach or gastroesophageal junction cancer.
- HER2 Positive Gastric Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does the FDA sanction Cinrebafusp alfa (PRS-343) in conjunction with ramucirumab and paclitaxel?
"With no proven efficacy yet, but with data indicating safety, our experts at Power have rated the combination of Cinrebafusp alfa (PRS-343), ramucirumab and paclitaxel a 2."
How widely accessible is this research endeavor?
"As of now, the study is being conducted in four locations; these cities consist of Santa Barbara, Houston and New york among a few others. To reduce transit burden for participants, it is beneficial to select the site most proximal to your place of residence if you decide to join."
What is the aggregate amount of participants enrolled in this trial?
"Presently, this research is not open for enrolling new participants. The trial was first listed on November 1st 2021 and underwent its most recent update September 7th 2022. If you are hunting for other studies that may suit your needs, there are 1173 trials recruiting persons with stomach cancer and 875 trials looking to recruit patients who will receive PRS-343 in conjunction with ramucirumab as well as paclitaxel."
What situations warrant the combination of Cinrebafusp alfa (PRS-343), ramucirumab, and paclitaxel?
"Cinrebafusp alfa (PRS-343) can be utilized in conjunction with ramucirumab and paclitaxel to treat various conditions including locally advanced non-small cell lung cancer, metastatic bladder cancer, and acquired immunodeficiency syndrome."
Are there any ongoing opportunities for individuals to participate in this research?
"This research programme is no longer accepting recruits. It was initially released on November 1st 2021 and then last amended on September 7th 2022. However, there are 1173 clinical trials for stomach cancer that are open to new participants and 875 studies recruiting patients interested in the combination of Cinrebafusp alfa (PRS-343), ramucirumab, and paclitaxel."
Could you please detail the previous research that has been conducted using PRS-343 alongside ramucirumab and paclitaxel?
"At present, 875 clinical trials are being conducted to investigate the efficacy of Cinrebafusp alfa (PRS-343), ramucirumab and paclitaxel. Of these studies, 234 have entered Phase 3 with Woolloongabba in Queensland acting as a major research hub. Furthermore, 49079 sites across the globe are evaluating this potential therapy."
Share this study with friends
Copy Link
Messenger